People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Other, Biotech / Pharma, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AYRO, Inc. | — | Other | Series C | $108.6M | $43.5M | 2016 |
| Akers Biosciences, Inc. | — | Biotech / Pharma | Series B | $78.7M | $30.5M | 2022 |
| Femasys Inc | — | Biotechnology | Series B | $74.7M | $32.0M | 2023 |
| Synaptogenix, Inc. | — | Biotechnology | Series A | $66.8M | $31.1M | 2025 |
| Calysta, Inc. | — | Biotechnology | Series C | $50.2M | $1.9B | 2011 |
| Neurotrope, Inc. | — | Biotechnology | Series B | $40.9M | $972.6M | 2016 |
| Marker Therapeutics, Inc. | — | Biotechnology | Series B | $29.8M | $93.5M | 2017 |
| Skype Global S.a r.l. | — | Other Technology | Series A | $7.8M | $215.1M | 2010 |
Joshua Silverman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joshua Silverman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Bernstein | 3 | 5 |
| Robert Weinstein | 2 | 6 |
| John Abeles | 2 | 4 |
| James New | 2 | 2 |
| William Singer | 2 | 2 |
| Joshua C. Silverman | 2 | 2 |
| Ralph Bean | 2 | 2 |
| John Wilson | 1 | 11 |
| DAVID ALLEN | 1 | 9 |
| Charles Giancarlo | 1 | 9 |
| David Hayes | 1 | 7 |
| Charles Larsen | 1 | 7 |
| Mark Adams | 1 | 7 |
| John Adams | 1 | 6 |
| Parker H. Petit | 1 | 5 |
| David Newman | 1 | 5 |
| Steven Elms | 1 | 5 |
| Bill White | 1 | 5 |
| James Davidson | 1 | 5 |
| Craig Eagle | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.